Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.40 |
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490339 | 0.95 | GAA (0.62) | GAAKDM4EMAPTNR1H3ALOX15 | |
| SCHEMBL11358716 | 0.89 | DRD2 (0.51) | GAAKDM4EMAPTNR1H3ALOX15 | |
| SCHEMBL3620189 | 0.85 | GAA (0.58) | GAAKDM4EMAPTALOX15HSD17B10 | |
| SCHEMBL7385186 | 0.84 | GAA (0.52) | GAAKDM4EMAPTALOX15HSD17B10 | |
| SCHEMBL11359502 | 0.81 | GAA (0.47) | GAAKDM4EMAPTNR1H3NR1H2 | |
| SCHEMBL3623628 | 0.79 | GAA (0.43) | GAANR1H3ALOX15HSD17B10NR1H2 | |
| SCHEMBL3717613 | 0.79 | GAA (0.57) | GAAKDM4EMAPTALOX15HSD17B10 | |
| SCHEMBL19185633 | 0.78 | GAA (0.49) | GAAKDM4EMAPTALOX15HSD17B10 | |
| SCHEMBL11356206 | 0.77 | DRD2 (0.49) | GAAKDM4EMAPTNR1H3ALOX15 | |
| SCHEMBL3626558 | 0.77 | GAA (0.41) | GAANR1H3ALOX15HSD17B10NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392567-B1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-1951676-B1 | N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-4218448-A | Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
| US-4107303-A | Antihypertensive hexafluorohydroxyisopropyl benzazepines and benzazocines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | GAA 3816/4885KDM4E 1452/4885MAPT 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.